STXS (Stereotaxis) Beta: 1.1148 (As of Jun. 25, 2026)


STXS Stereotaxis Inc STXS
66 GF Score
Price $1.66
GF Value $2.31
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Stereotaxis Beta?

Stereotaxis STXS +1.53% 66 Beta is 1.1148 as of Jun. 25, 2026. GuruFocus rates STXS with a GF Score™ of 66/100 and a GF Value™ of $2.31 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Stereotaxis's Beta is 1.1148.


Stereotaxis  (AMEX:STXS) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Stereotaxis Beta Related Terms


Stereotaxis Beta Historical Data

* Premium members only.

The historical data trend for Stereotaxis's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stereotaxis Beta Chart

Stereotaxis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.42 1.83 1.24 1.25 0.71

Stereotaxis Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.33 1.01 0.92 0.71 1.13

STXS vs EMBC, KRMD, PDEX: Beta Comparison

For the Medical Instruments & Supplies subindustry, Stereotaxis's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stereotaxis Beta vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Stereotaxis's Beta distribution charts can be found below:

* The bar in red indicates where Stereotaxis's Beta falls into.


STXS
66GF Score
Stereotaxis Inc STXS
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Stereotaxis Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.1148 mean?
Stereotaxis (STXS) has a Beta of 1.1148 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Stereotaxis and its competitors.
Is Stereotaxis' Beta too high?
Stereotaxis' current Beta is 1.1148. Overall, Stereotaxis has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Stereotaxis' Beta compare to EMBC and KRMD?
Stereotaxis' Beta of 1.1148 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Stereotaxis and its competitors. Stereotaxis's current Beta is 1.1148. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stereotaxis stock overvalued right now?
Based on GuruFocus' analysis, Stereotaxis (STXS) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.31, compared to a current price of $1.66 — trading 28.4% below its estimated fair value. The current Beta is 1.1148. Stereotaxis' overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Stereotaxis (STXS), the current Beta is 1.1148 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Stereotaxis (STXS) Overvalued in 2026?

Based on GuruFocus' analysis, Stereotaxis stock appears to be undervalued. The current stock price of $1.66 is trading 28.4% below its estimated GF Value™ of $2.31. GuruFocus considers Stereotaxis to be Modestly Undervalued.

Key valuation signals for STXS:

  • Beta: 1.1148
  • GF Value™: $2.31 vs. price of $1.66 (28.4% below fair value)
  • GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the STXS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Stereotaxis Business Description

Other Exchanges RJR1:Germany
Address 710 North Tucker Boulevard, Suite 110, St. Louis, MO, USA, 63101
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.
66GF Score

Get the complete analysis for STXS

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.66
Price
$2.31
GF Value